ArticleFrontiers in oncology2025
Prognostic risk factors and the role of systemic inflammatory response index in predicting outcomes for non-muscle-invasive bladder cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of systemic inflammatory response index in patients with bladder cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Risk factors for recurrence after initial transurethral resection of bladder tumor in patients with non-muscle-invasive bladder cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-muscle-invasive bladder cancer (NMIBC) presents a variable prognosis, with a significant risk of recurrence and progression. Traditional clinicopathological factors provide limited prognostic accuracy, necessitating additional biomarkers. This study aimed to evaluate the prognostic role of the systemic inflammatory response index (SIRI) and traditional risk factors in predicting outcomes in NMIBC patients. Methods: We retrospectively analyzed 158 NMIBC patients who underwent transurethral resection of bladder tumor (TURBT) between January 2021 and October 2023. Patients were stratified into recurrence/non-recurrence and progression/non-progression groups. Clinical and pathological characteristics were compared using Chi-square tests, t-tests, or Fisher's exact tests as appropriate. Receiver operating characteristic (ROC) analysis identified the optimal SIRI cutoff, which was used for Kaplan-Meier survival analysis and Cox regression to assess independent prognostic factors for progression-free survival (PFS). Results: The optimal SIRI cutoff value for predicting progression was 0.716 (area under the curve [AUC] = 0.689, sensitivity = 0.689, specificity = 0.718). Patients with SIRI ≥ 0.716 exhibited significantly higher progression risk (P = 0.012) and poorer PFS (Log-rank P < 0.05). Multivariate Cox regression confirmed tumor count (HR = 3.273, 95% CI: 1.003-10.691, P = 0.049), primary diagnosis status (HR = 2.563, 95% CI: 1.012-7.214, P = 0.045), and high SIRI (HR = 2.979, 95% CI: 1.110-8.027, P = 0.031) as independent predictors of PFS. Recurrence analysis further revealed that high SIRI was associated with markedly increased recurrence rates in both Ta (50.0% vs. 6.2%, P < 0.001) and T1 subgroups (73.9% vs. 32.3%, P < 0.001). Conclusions: SIRI is a significant predictor of disease progression in NMIBC, although it is not associated with RFS. When combined with clinicopathological factors such as tumor stage, grade, count, and primary diagnosis status, SIRI can enhance risk stratification in NMIBC, aiding personalized management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.